PubMed HealthSearch

Biomedical subjects

Andrea Menicucci

Publications and source records attributed to Andrea Menicucci.

2 recordsLinked to original sources

In genomes we trust: Assessing genomic reliability within the family Nectriaceae.

Reliable evolutionary inference increasingly depends on public genome resources, and the effects of uneven assembly quality, incomplete metadata, and biased taxonomic sampling remain poorly quantified. Using the species-rich fungal lineage Nectriaceae as a model system, we analysed 1530 genome sequence assemblies to assess metadata completeness, sampling representation, and genome quality. One-third of the assemblies lacked essential metadata, sequencing was heavily skewed toward a few agriculturally important lineages, and sampling of many genera was limited or nonexistent. BUSCO and QUAST metrics revealed substantial heterogeneity in assembly quality, with widespread fragmentation and numerous assemblies falling outside expected quality thresholds. From 763 single-copy orthologs identified in 576 higher-quality genomes, we reconstructed a phylogenomic backbone and quantified gene- and site-level concordance across the tree. Although major clades were broadly recovered, extensive gene-tree discordance and a polyphyletic Fusarium nisikadoi species complex revealed unresolved boundaries and conflict among loci. These results show how data quality, incomplete sampling, and discordant genomic histories can constrain phylogenomic resolution, and provide a general framework for improving comparative genomic resources and large-scale evolutionary inference.

Gene-tree discordance

MammaPrint predicts chemotherapy benefit in HR+HER2- early breast cancer: FLEX Registry real-world data.

BACKGROUND: Gene expression assays help personalize adjuvant chemotherapy decisions for hormone receptor-positive, HER2-negative (HR+HER2-) early breast cancer (EBC). The 70-gene risk of distant-recurrence signature, MammaPrint, demonstrated clinical utility in guiding chemotherapy de-escalation in genomically low risk patients in the MINDACT trial. This study evaluates MammaPrint as a continuous predictor of chemotherapy benefit in HR+HER2- EBC using real-world data (RWD) from the FLEX Registry. METHODS: The study evaluated 1002 patients treated with endocrine therapy (ET) only or ET with chemotherapy (ET+CT) enrolled in FLEX (NCT03053193) with 5-year median follow-up. Propensity-score matching balanced treatment groups by menopausal status, T-stage, and nodal status. The primary endpoint was distant recurrence-free interval (DRFI). Regression and Cox proportional hazards models assessed chemotherapy benefit across MammaPrint Index (MPI) risk. RESULTS: Most patients were postmenopausal (70.1%), node-negative (70.0%), and had grade 2 tumors (51.2%). The regression models showed that MPI strongly predicted 5-year DRFI in ET only (R2 = 0.99, P&#x2009;<&#x2009;.001) and ET + CT (R2 = 0.90, P&#x2009;<&#x2009;.001) groups, corresponding to an average absolute chemotherapy benefit of 5.6% in High 1 and 10.9% in High 2. Minimal improvement in DRFI with chemotherapy was observed for Low (1.7%) and UltraLow (<1.0%) risk groups. A multivariate Cox model with an MPI-by-treatment interaction term demonstrated that increasing MPI risk was associated with greater chemotherapy benefit on DRFI (HR&#x2009;=&#x2009;0.15, P&#x2009;=&#x2009;.047). Chemotherapy benefit was significantly associated with premenopausal status, but not age, T-stage, nodal status, or grade. CONCLUSIONS: These RWD from the FLEX Registry demonstrate that MPI is predictive of both DRFI prognosis and chemotherapy benefit in HR+HER2- EBC. (NCT03053193).

Adult